C C Dvorak

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data
    Christopher C Dvorak
    Division of Pediatric Blood and Marrow Transplant, Department of Pediatrics, University of California San Francisco, San Francisco, California 94143 1278, USA
    Pediatr Blood Cancer 59:21-6. 2012
  2. ncbi Safety of hematopoietic stem cell transplantation in children less than three years of age
    Christopher C Dvorak
    Division of Pediatric Stem Cell Transplantation, Stanford University School of Medicine, Stanford, CA, USA
    Pediatr Hematol Oncol 25:705-22. 2008
  3. ncbi Development of herpes simplex virus stomatitis during receipt of cidofovir therapy
    Christopher C Dvorak
    Division of Pediatric Blood and Marrow Transplant, University of California, San Francisco, California 94143 1278, USA
    Clin Infect Dis 49:e92-5. 2009
  4. ncbi Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions
    C C Dvorak
    UCSF Children s Hospital, University of California, San Francisco, USA
    Bone Marrow Transplant 44:805-12. 2009
  5. ncbi Maternal T-cell engraftment associated with severe hemophagocytosis of the bone marrow in untreated X-linked severe combined immunodeficiency
    Christopher C Dvorak
    Division of Pediatric Stem Cell Transplantation, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
    J Pediatr Hematol Oncol 30:396-400. 2008
  6. ncbi Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia
    Christopher C Dvorak
    Division of Pediatric Blood and Marrow Transplantation, University of California, San Francisco, California 94143 1278, USA
    Biol Blood Marrow Transplant 14:824-30. 2008
  7. ncbi Primary graft failure after umbilical cord blood transplant rescued by parental haplocompatible stem cell transplantation
    Christopher C Dvorak
    Division of Pediatric Blood and Marrow Transplant, UCSF Children s Hospital, University of California, San Francisco, CA, USA
    J Pediatr Hematol Oncol 31:300-3. 2009
  8. ncbi Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34(+) cells and a fixed CD3(+) dose
    C C Dvorak
    Department of Pediatrics, Division of Allergy, Immunology, and Blood and Marrow Transplant, UCSF Benioff Children s Hospital, University of California San Francisco, San Francisco, CA, USA
    Bone Marrow Transplant 48:508-13. 2013
  9. ncbi Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation
    C C Dvorak
    Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation, Stanford University School of Medicine, Palo Alto, CA 94304, USA
    Bone Marrow Transplant 36:621-9. 2005
  10. ncbi Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders
    E Ozyurek
    Department of Pediatrics, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA
    Bone Marrow Transplant 42:83-91. 2008

Collaborators

Detail Information

Publications15

  1. ncbi Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data
    Christopher C Dvorak
    Division of Pediatric Blood and Marrow Transplant, Department of Pediatrics, University of California San Francisco, San Francisco, California 94143 1278, USA
    Pediatr Blood Cancer 59:21-6. 2012
    ..The echinocandins are well-tolerated, but only available in intravenous form. Ultimately, studies demonstrating biologic risk factors for the development of IFI may lead to personalized prophylactic strategies...
  2. ncbi Safety of hematopoietic stem cell transplantation in children less than three years of age
    Christopher C Dvorak
    Division of Pediatric Stem Cell Transplantation, Stanford University School of Medicine, Stanford, CA, USA
    Pediatr Hematol Oncol 25:705-22. 2008
    ..Cyclophosphamide-related perineal dermatitis is a unique complication in very young children. Finally, the incidence of acute and chronic GvHD in this population is low...
  3. ncbi Development of herpes simplex virus stomatitis during receipt of cidofovir therapy
    Christopher C Dvorak
    Division of Pediatric Blood and Marrow Transplant, University of California, San Francisco, California 94143 1278, USA
    Clin Infect Dis 49:e92-5. 2009
    ..All patients responded well to treatment with either acyclovir or ganciclovir. Despite the in vitro susceptibility of HSV to cidofovir, once-weekly treatment with this agent may not be adequate prophylaxis in pediatric patients...
  4. ncbi Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions
    C C Dvorak
    UCSF Children s Hospital, University of California, San Francisco, USA
    Bone Marrow Transplant 44:805-12. 2009
    ..The 1-year overall survival following haplocompatible DLI was 71% (95% CI, 59-83%), with a median follow-up of 16 months from the first DLI...
  5. ncbi Maternal T-cell engraftment associated with severe hemophagocytosis of the bone marrow in untreated X-linked severe combined immunodeficiency
    Christopher C Dvorak
    Division of Pediatric Stem Cell Transplantation, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
    J Pediatr Hematol Oncol 30:396-400. 2008
    ..Hemophagocytosis was most likely owing to maternal graft-versus-host disease, as perforin-expressing CD8 T cells, presumably of maternal origin, were prominent in the bone marrow and there was no concurrent severe infection...
  6. ncbi Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia
    Christopher C Dvorak
    Division of Pediatric Blood and Marrow Transplantation, University of California, San Francisco, California 94143 1278, USA
    Biol Blood Marrow Transplant 14:824-30. 2008
    ..Autologous HSCT is associated with a low incidence of TRM, whereas allogeneic HSCT is associated with a low incidence of relapse, suggesting a strong GVL effect against residual APL...
  7. ncbi Primary graft failure after umbilical cord blood transplant rescued by parental haplocompatible stem cell transplantation
    Christopher C Dvorak
    Division of Pediatric Blood and Marrow Transplant, UCSF Children s Hospital, University of California, San Francisco, CA, USA
    J Pediatr Hematol Oncol 31:300-3. 2009
    ....
  8. ncbi Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34(+) cells and a fixed CD3(+) dose
    C C Dvorak
    Department of Pediatrics, Division of Allergy, Immunology, and Blood and Marrow Transplant, UCSF Benioff Children s Hospital, University of California San Francisco, San Francisco, CA, USA
    Bone Marrow Transplant 48:508-13. 2013
    ..Megadose CD34(+) cells with a fixed CD3(+) cell dose from haploidentical related donors resulted in good outcomes for pediatric patients with nonmalignant diseases and those with malignant diseases transplanted in remission...
  9. ncbi Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation
    C C Dvorak
    Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation, Stanford University School of Medicine, Palo Alto, CA 94304, USA
    Bone Marrow Transplant 36:621-9. 2005
    ..Thus, IFI is a significant cause of nonrelapse mortality in children undergoing allogeneic HCT and more effective strategies are needed to prevent and treat IFI...
  10. ncbi Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders
    E Ozyurek
    Department of Pediatrics, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA
    Bone Marrow Transplant 42:83-91. 2008
    ..Additional studies of post transplant chimerism are required to improve our ability to accurately identify children at risk of graft loss following transplant for non-malignant disorders...
  11. ncbi Hematopoietic stem cell transplantation for primary immunodeficiency disease
    C C Dvorak
    Department of Pediatrics, UCSF Children s Hospital, San Francisco, CA 94143 1278, USA
    Bone Marrow Transplant 41:119-26. 2008
    ..The role of pretransplant conditioning in patients with SCID disease in terms of its effects upon T- and B-cell immune reconstitution and late effects is still under debate and will require further study...
  12. ncbi Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs
    S C Kussmaul
    Pediatric Infectious Diseases, San Francisco Children s Hospital, University of California San Francisco, 500 Parnassus Avenue, San Francisco, CA 94143, USA
    Bone Marrow Transplant 45:1602-6. 2010
    ..It appears safe to administer the LAVV to immunocompetent patients after HSCT. Prospective studies are needed to more accurately determine rates of vaccine complications, efficacy and immunologic responses to vaccination...
  13. ncbi Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation
    Christopher C Dvorak
    Division of Pediatric Blood and Marrow Transplant, University of California San Francisco Children s Hospital, San Francisco, CA, USA
    Biol Blood Marrow Transplant 14:1125-33. 2008
    ....
  14. ncbi Radiosensitive severe combined immunodeficiency disease
    Christopher C Dvorak
    Division of Pediatric Blood and Marrow Transplantation, University of California, San Francisco, 505 Parnassus Avenue, M 659, San Francisco, CA 94143 1278, USA
    Immunol Allergy Clin North Am 30:125-42. 2010
    ....
  15. ncbi Optimizing care for GI disorders in children after hematopoietic stem cell transplantation
    William Berquist
    Gastrointest Endosc 64:386-8. 2006